HDL Cholesterol Clinical Trial
Official title:
Effect of Niaspan on Parameters of Reverse Cholesterol Transport and HDL-C Subclasses in Male Subjects With Low HDL-C Levels
To determine whether 8 weeks of Niaspan treatment increases cholesterol efflux in male
subjects with low HDL-C cholesterol when compared to no treatment.
To determine whether 8 weeks of Niaspan treatment increases fecal cholesterol excretion when
compared to no treatment.
To determine whether 8 weeks of Niaspan treatment increases the rate of global reverse
cholesterol transport when compared to no treatment.
This will be a single center, open-label, randomized, mechanism of action study consisting of 8 weeks of active treatment preceded by a screening phase from one to 8 weeks and a baseline measurement of parameters of reverse cholesterol transport for 10 days. The population for this trial is 15 non-diabetic men aged 18-70 years. Ten subjects will be low HDL-C male volunteers who will receive aspirin and Niaspan and five subjects will be low HDL-C male volunteers who will receive only aspirin. ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
| Active, not recruiting |
NCT00238004 -
The Low HDL On Six Weeks Statin Therapy (LOW) Study
|
Phase 4 | |
| Completed |
NCT00389896 -
A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)
|
Phase 3 | |
| Recruiting |
NCT00736463 -
Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)
|
Phase 4 | |
| Completed |
NCT00809068 -
High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone
|
Phase 4 |